223 related articles for article (PubMed ID: 22332960)
21. Treatment of Adults with Lennox-Gastaut Syndrome: Further Analysis of Efficacy and Safety/Tolerability of Rufinamide.
McMurray R; Striano P
Neurol Ther; 2016 Jun; 5(1):35-43. PubMed ID: 26861566
[TBL] [Abstract][Full Text] [Related]
22. Dosing considerations for rufinamide in patients with Lennox-Gastaut syndrome: Phase III trial results and real-world clinical data.
Kothare S; Kluger G; Sachdeo R; Williams B; Olhaye O; Perdomo C; Bibbiani F
Seizure; 2017 Apr; 47():25-33. PubMed ID: 28284045
[TBL] [Abstract][Full Text] [Related]
23. Rufinamide.
Deeks ED; Scott LJ
CNS Drugs; 2006; 20(9):751-60; discussion 761. PubMed ID: 16953653
[TBL] [Abstract][Full Text] [Related]
24. lennox-Gastaut syndrome: an updateon treatment.
Carmant L; Whiting S
Can J Neurol Sci; 2012 Nov; 39(6):702-11. PubMed ID: 23227575
[TBL] [Abstract][Full Text] [Related]
25. Role of rufinamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy).
Kluger G; Bauer B
Neuropsychiatr Dis Treat; 2007 Feb; 3(1):3-11. PubMed ID: 19300535
[TBL] [Abstract][Full Text] [Related]
26. Clobazam : in patients with Lennox-Gastaut syndrome.
Yang LP; Scott LJ
CNS Drugs; 2012 Nov; 26(11):983-91. PubMed ID: 23034582
[TBL] [Abstract][Full Text] [Related]
27. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study.
Arzimanoglou A; Ferreira JA; Satlin A; Mendes S; Williams B; Critchley D; Schuck E; Hussein Z; Kumar D; Dhadda S; Bibbiani F
Eur J Paediatr Neurol; 2016 May; 20(3):393-402. PubMed ID: 26805435
[TBL] [Abstract][Full Text] [Related]
28. Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide.
Schimpf R; Veltmann C; Papavassiliu T; Rudic B; Göksu T; Kuschyk J; Wolpert C; Antzelevitch C; Ebner A; Borggrefe M; Brandt C
Heart Rhythm; 2012 May; 9(5):776-81. PubMed ID: 22245794
[TBL] [Abstract][Full Text] [Related]
29. Current role of rufinamide in the treatment of childhood epilepsy: literature review and treatment guidelines.
Coppola G; Besag F; Cusmai R; Dulac O; Kluger G; Moavero R; Nabbout R; Nikanorova M; Pisani F; Verrotti A; von Stülpnagel C; Curatolo P
Eur J Paediatr Neurol; 2014 Nov; 18(6):685-90. PubMed ID: 24929673
[TBL] [Abstract][Full Text] [Related]
30. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome.
Glauser T; Kluger G; Sachdeo R; Krauss G; Perdomo C; Arroyo S
Neurology; 2008 May; 70(21):1950-8. PubMed ID: 18401024
[TBL] [Abstract][Full Text] [Related]
31. Short-term efficacy and tolerability of rufinamide adjunctive therapy in children with refractory generalised epilepsy.
Kim SH; Lee JH; Ryu HW; Lim BC; Chae JH; Choi JE; Hwang YS; Kim KJ
Epileptic Disord; 2013 Mar; 15(1):49-54. PubMed ID: 23531645
[TBL] [Abstract][Full Text] [Related]
32. Expert opinion: Proposed diagnostic and treatment algorithms for Lennox-Gastaut syndrome in adult patients.
Montouris G; Aboumatar S; Burdette D; Kothare S; Kuzniecky R; Rosenfeld W; Chung S
Epilepsy Behav; 2020 Sep; 110():107146. PubMed ID: 32563898
[TBL] [Abstract][Full Text] [Related]
33. Rufinamide in children and adults in routine clinical practice.
Jaraba S; Santamarina E; Miró J; Toledo M; Molins A; Burcet J; Becerra JL; Raspall M; Pico G; Miravet E; Cano A; Fossas P; Fernández S; Falip M
Acta Neurol Scand; 2017 Jan; 135(1):122-128. PubMed ID: 26923380
[TBL] [Abstract][Full Text] [Related]
34. Treating Lennox-Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide.
Gresham J; Eiland LS; Chung AM
Neuropsychiatr Dis Treat; 2010 Oct; 6():639-45. PubMed ID: 20957124
[TBL] [Abstract][Full Text] [Related]
35. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA).
Hahn CD; Jiang Y; Villanueva V; Zolnowska M; Arkilo D; Hsiao S; Asgharnejad M; Dlugos D
Epilepsia; 2022 Oct; 63(10):2671-2683. PubMed ID: 35841234
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience.
Kluger G; Kurlemann G; Haberlandt E; Ernst JP; Runge U; Schneider F; Makowski C; Boor R; Bast T
Epilepsy Behav; 2009 Mar; 14(3):491-5. PubMed ID: 19162229
[TBL] [Abstract][Full Text] [Related]
37. Budget impact analysis of antiepileptic drugs for Lennox-Gastaut syndrome.
Skornicki M; Clements KM; O'Sullivan AK
J Manag Care Spec Pharm; 2014 Apr; 20(4):400-6. PubMed ID: 24684645
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to <4 years old) with Lennox-Gastaut syndrome: Final results from randomized study 303.
Arzimanoglou A; Ferreira J; Satlin A; Olhaye O; Kumar D; Dhadda S; Bibbiani F
Eur J Paediatr Neurol; 2019 Jan; 23(1):126-135. PubMed ID: 30309816
[TBL] [Abstract][Full Text] [Related]
39. Rufinamide efficacy and safety as adjunctive treatment in children with focal drug resistant epilepsy: the first Italian prospective study.
Moavero R; Cusmai R; Specchio N; Fusco L; Capuano A; Curatolo P; Vigevano F
Epilepsy Res; 2012 Nov; 102(1-2):94-9. PubMed ID: 22677424
[TBL] [Abstract][Full Text] [Related]
40. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.
Wilby J; Kainth A; Hawkins N; Epstein D; McIntosh H; McDaid C; Mason A; Golder S; O'Meara S; Sculpher M; Drummond M; Forbes C
Health Technol Assess; 2005 Apr; 9(15):1-157, iii-iv. PubMed ID: 15842952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
